Biostabilized ex vivo human skin model

A versatile ex vivo human skin model

designed for testing injectable therapeutics


Biostabilized & functional

  • viable and functional for 7+ days
  • immunocompetent
  • contains 14 immune cell types naturally presented in human skin

Multiple administration routes

  • subcutaneous & intradermal injections
  • topical & transdermal applications
  • systemic-like administration

Hyposkin a versatile ex vivo model designed for injectable therapeutics

More about HypoSkin capabilities?

Cutting-edge data analysis for relevant results

Get the whole picture before you move forward

To help you obtain the full picture of how skin and immune cells respond to your formula, our expertise includes unbiased data analysis via artificial intelligence, spatial biology for specific applications.

Biological & immunological validation

Human skin structure and its resident immune system are maintained for 7 days


Since we use real human skin to generate HypoSkin®, it has the same structure and composition as in vivo human skin. Hematoxylin & Eosin staining confirms the preservation of tissue and cellular structures across all three skin layers (epidermis, dermis, and hypodermis). Visual examination reveals a mature stratum corneum, a dermal-epidermal junction mirroring real human skin, and intact basal layers and rete ridges. Notably, the images also demonstrate the sustained integrity of HypoSkin® for a duration of up to 7 days.

HypoSkin Epidermis & Papillary Dermis - Day 0
Epidermis & Papillary Dermis - Day 0
HypoSkin Epidermis & Papillary Dermis - Day 3
Epidermis & Papillary Dermis - Day 3
HypoSkin Epidermis & Papillary Dermis - Day 7
Epidermis & Papillary Dermis - Day 7
HypoSkin Reticular Dermis - Day 0
Reticular Dermis - Day 0
HypoSkin Reticular Dermis - Day 3
Reticular Dermis - Day 3
HypoSkin Reticular Dermis - Day 7
Reticular Dermis - Day 7
HypoSkin Subcutaneous tissue - Day 0
Subcutaneous tissue - Day 0
HypoSkin Subcutaneous tissue - Day 3
Subcutaneous tissue - Day 3
HypoSkin Subcutaneous tissue - Day 7
Subcutaneous tissue - Day 7

Presence of skin-resident immune cells at 7 days

Genoskin’s proprietary technology enables the maintenance of all skin-resident immune cells for over a week during experimentation.

Diversity of myeloid cells in HypoSkin® at D1 of culture. Acquisition made thanks to our proprietary spatial biology solution, MANTIS and using the Myeloid Cells panel
single-cell RNA sequencing of the HypoSkin® human skin model. Genoskin technology maintains immune and structural cell distribution across different population overtime (up to 10 days)

Figure 1 shows immune cells are characterized in HypoSkin® using the MANTIS® spatial biology platform  (myeloid panel: Langerhans, Dendritic cells, Mast cells, Macrophages…). Figure 2 shows the cell distribution across different population over time (colored based on the day of sampling).

Functional and activatable skin-resident human immune cells

HypoSkin® remains fully living and immunocompetent throughout a 7-day experimental period. This enables longitudinal secretome analysis for evaluating the toxicity and efficacy of therapeutic and chemical compounds.

Heatmap of the log2 fold change of the cytokines concentrations in clinical-grade water vs vaccine injected modules after 8h and 24h on 6 different donors.

Fold change of cytokines concentrations in clinical-grade water vs vaccine injected HypoSkin® skin model after 8h and 24h in 6 different donors.

More information about Genoskin services for injectable compounds?

Toxicity assessment, Vaccine development, Tolerability of Drug Delivery System and Medical Device and more.

Scientific publications using HypoSkin®

See how others use the HypoSkin® model to generate results


August 2022 - Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology

November 2021 - A suspended layer additive manufacturing approach to the bioprinting of tri-layered skin equivalents

July 2021 - Poster - Mitigation of Injection Site Reactions after Subcutaneous Administration of Dalcinonacog Alfa (DalcA) in Hemophilia B Using Preclinical Models

July 2021 - Poster - Assessing subcutaneous injection site reactions by leveraging immunocompetent human skin and artificial intelligence

December 2020 - Standalone or combinatorial phenylbutyrate therapy shows excellent antiviral activity and mimics CREB3 silencing

August 2019 - Near-infrared light activable hydrogels for metformin delivery

  • Near-infrared light activable hydrogels for metformin delivery
    • Published in Nanoscale – 2019 Aug 29;11(34):15810-15820
      • Li Chengnan, Quentin Pagneux, Anna Voronova, Alexandre Barras, Amar Abderrahmani, Valérie Plaisance, Valerie Pawlowski, Nathalie Hennuyer, Bart Staels, Lea Rosselle, Nadia Skandrani, Musen Li, Rabah Boukherroub, Sabine Szunerits

December 2018 - Poster - A fully functional ex vivo human skin model to study human skin microbiome

January 2018 - Poster - Evaluation of local inflammatory reactions following subcutaneous injection of a pro-inflammatory cocktail in a fully human ex vivo skin model

Not sure if HypoSkin® is the model you need?

Don’t hesitate to get in touch to explain your project. Our experts are here to help you out.